{"id":459,"date":"2022-04-20T10:25:34","date_gmt":"2022-04-20T10:25:34","guid":{"rendered":"https:\/\/www.ub.edu\/tpdlab\/?p=459"},"modified":"2022-05-02T10:21:21","modified_gmt":"2022-05-02T10:21:21","slug":"new-spin-off-company-oniria-therapeutics-sets-out-to-counteract-cancer-resistance-combat-disease-relapse","status":"publish","type":"post","link":"https:\/\/www.ub.edu\/tpdlab\/2022\/04\/20\/new-spin-off-company-oniria-therapeutics-sets-out-to-counteract-cancer-resistance-combat-disease-relapse\/","title":{"rendered":"New spin off company ONIRIA Therapeutics sets out to counteract cancer resistance &#038; combat disease relapse"},"content":{"rendered":"<p style=\"text-align: justify;\">We are proud to announce that Carles and Xavi co-founded <a href=\"https:\/\/www.oniriatherapeutics.com\/\">Oniria Therapeutics<\/a>, a new spin-off launched on March 2022. The Vall d\u2019Hebron Institute of Oncology (VHIO), Universidad de Barcelona (UB), and the ICREA Catalan Institution for Research and Advanced Studies, have joined forces to create it. Oniria aims to modulate cell dormancy to overcome cancer persistance with novel therapeutic approaches.<br>\nYou can read the entire post <a href=\"https:\/\/www.vhio.net\/new-spin-off-company-oniria-therapeutics-founded-by-vhio-ub-and-icrea-with-the-support-of-la-caixa-aecc-and-isciii-sets-out-to-counteract-cancer-resistance-combat-disease-relap\/\">here<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-461 size-full\" src=\"https:\/\/www.ub.edu\/tpdlab\/wp-content\/uploads\/2022\/04\/Oniria_IMG-20211223-WA0008.jpg\" alt=\"\" width=\"1024\" height=\"768\" srcset=\"https:\/\/www.ub.edu\/tpdlab\/wp-content\/uploads\/2022\/04\/Oniria_IMG-20211223-WA0008.jpg 1024w, https:\/\/www.ub.edu\/tpdlab\/wp-content\/uploads\/2022\/04\/Oniria_IMG-20211223-WA0008-300x225.jpg 300w, https:\/\/www.ub.edu\/tpdlab\/wp-content\/uploads\/2022\/04\/Oniria_IMG-20211223-WA0008-768x576.jpg 768w, https:\/\/www.ub.edu\/tpdlab\/wp-content\/uploads\/2022\/04\/Oniria_IMG-20211223-WA0008-732x549.jpg 732w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/p>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We are proud to announce that Carles and Xavi co-founded Oniria Therapeutics, a new spin-off launched on March 2022. The Vall d\u2019Hebron Institute of Oncology (VHIO), Universidad de Barcelona (UB), and the ICREA Catalan Institution for Research and Advanced Studies, have joined forces to create it. Oniria aims to modulate cell dormancy to overcome cancer [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-459","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/posts\/459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/comments?post=459"}],"version-history":[{"count":3,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/posts\/459\/revisions"}],"predecessor-version":[{"id":464,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/posts\/459\/revisions\/464"}],"wp:attachment":[{"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/media?parent=459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/categories?post=459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ub.edu\/tpdlab\/wp-json\/wp\/v2\/tags?post=459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}